DTC TRT Success

A direct-to-consumer TRT (Testosterone Replacement Therapy) business that makes the process of getting treatment more accessible and streamlined.

Key Points:

• Market Validation:

  • Company referenced (Hone) is "doing fantastic"
  • Every update shows strong performance
  • Initial investment was at $10-15M valuation
  • Current estimated value is "9 figures"

• Business Model:

  • Direct-to-consumer approach
  • Makes TRT treatment more accessible
  • Streamlines the traditional process of getting treatment

• Investment Success:

  • Both speakers invested in Hone
  • Described as "gangbusters" performance
  • Estimated 10x return on investment value

• Market Timing:

  • Identified as an opportunity in 2020-2021
  • Proven successful through Hone's performance
  • Part of broader trend in men's health services

Note: The speakers identified this as a "fantastic idea" they both invested in rather than started themselves, with the success validating their prediction about the market opportunity.